Exposure to topical minoxidil, estrogen, and corticosteroids is also linked to poisoning in cats and dogs, in a review of 27 ...
Singer Siu Black has overcome the critical condition and regained consciousness after a day of intensive treatment at Hung ...
First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation - ...
Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to ...
Servier today announced that it will present new and updated data at the 67th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2025, in Orlando, Florida. Presentations will ...
Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...
Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...
The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback